PulmonologyNews.net

Pulmonology Xagena

Xagena Mappa
Medical Meeting
Xagena Salute
XagenaNewsletter

Search results for "Non-small cell lung cancer"

When combined with standard chemotherapy, Vandetanib ( Zactima ) improves progression-free survival for patients with advanced non-small cell lung cancer. The findings, presented at the American ...


The results from its PRONOUNCE trial of Alimta ( Pemetrexed for injection ) for treatment of nonsquamous non-small cell lung cancer ( NSCLC ) have been presented at the American Society of Clinical On ...


Alectinib ( Alecensa ) is a second-generation, orally active, potent and highly selective inhibitor of anaplastic lymphoma kinase ( ALK ). Alectinib is approved for the treatment of ALK fusion-gen ...


Data were reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer ( WCLC ) 2015, in Denver, Colorado ( U.S. ). 25 abstracts ( including 9 oral ...


Epidermal growth factor receptor-tyrosine kinase inhibitors ( EGFR-TKIs ) are a critical member of systemic therapy for advanced non-small-cell lung cancer ( NSCLC ). Erlotinib ( Tarceva ) is the ...


MicroRNAs ( miRNAs ) are endogenous small ( 19-24 nt long ) noncoding RNAs that regulate gene expression in a sequence specific manner. An increasing association between miRNA and cancer has been re ...


Approximately 10% of EGFR mutants harbor uncommon mutations, which represent a heterogeneous group of rare molecular alterations within exons 18-21 and the sensitivity to EGFR tyrosine kinase inhibito ...


Alectinib ( Alecensa ) has proven systemic and CNS efficacy in patients with ALK+ aNSCLC ( advanced non-small cell lung cancer ) ( ALEX trial ). T umor cell death caused by Alectinib may release anti ...


Despite advancement of 2nd generation ALK tyrosine kinase inhibitors ( TKIs ), patients with ALK+ non-small cell lung cancer ( NSCLC ) continue to develop resistance and CNS metastases become more d ...


ALTA trial has evaluated 2 doses of the ALK inhibitor Brigatinib post-Crizotinib. Overall objective response rate ( ORR ) contains both CNS and extra-CNS target lesion data. In ALTA, stratification ...


CheckMate 227, a phase 3 study of first-line Nivolumab ( Opdivo ) plus Ipilimumab ( Yervoy ), Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy in advanced non-small cell lung cancer ( NSCLC ) ...


CheckMate 227 is a large phase 3 study of first-line Nivolumab plus Ipilimumab, Nivolumab, or Nivolumab plus chemotherapy vs chemotherapy in advanced non-small cell lung cancer ( NSCLC ). The stud ...


The phase 2 ATLANTIC study has investigated the anti-PD-L1 antibody Durvalumab ( Imfinzi ) in heavily pretreated patients with advanced non-small cell lung cancer ( NSCLC ). Researchers have repor ...